BioPharma Credit Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2017
Net Income	129.89	122.18	108.45	182.31	84.96	Upgrade
Loss (Gain) From Sale of Investments	-17.52	0.09	23.95	-5.95	23.75	Upgrade
Other Operating Activities	-0.04	0	0.01	0.03	0.02	Upgrade
Change in Accounts Receivable	-21.8	-11.48	-0.48	-9.83	-9.8	Upgrade
Change in Accounts Payable	0.56	1.12	-8.74	17.71	-2.49	Upgrade
Operating Cash Flow	91.1	111.91	123.18	184.28	96.44	Upgrade
Operating Cash Flow Growth	-18.60%	-9.15%	-33.15%	91.09%	66.06%	Upgrade
Investment in Securities	77.48	39.07	-1.66	48.19	-94.82	Upgrade
Investing Cash Flow	77.48	39.07	-1.66	48.19	-94.82	Upgrade
Repurchase of Common Stock	-51.27	-105.75	-17.22	-50.09	-	Upgrade
Common Dividends Paid	-79.96	-109.02	-68.95	-95.74	-96.17	Upgrade
Financing Cash Flow	-161.65	-280.42	-106.99	-206.62	-100.16	Upgrade
Foreign Exchange Rate Adjustments	0.04	-0	-0.01	-0.03	-0.02	Upgrade
Net Cash Flow	6.97	-129.43	14.53	25.82	-98.56	Upgrade
Levered Free Cash Flow	59.03	66.9	56.88	124.09	40.26	Upgrade
Unlevered Free Cash Flow	59.03	66.9	56.88	124.09	40.26	Upgrade
Change in Working Capital	-21.24	-10.36	-9.22	7.88	-12.29	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.